NVCT vs. CRBP, LXRX, SLRN, CTNM, IGMS, TERN, ALXO, VERV, CMPS, and ACIU
Should you be buying Nuvectis Pharma stock or one of its competitors? The main competitors of Nuvectis Pharma include Corbus Pharmaceuticals (CRBP), Lexicon Pharmaceuticals (LXRX), Acelyrin (SLRN), Contineum Therapeutics (CTNM), IGM Biosciences (IGMS), Terns Pharmaceuticals (TERN), ALX Oncology (ALXO), Verve Therapeutics (VERV), COMPASS Pathways (CMPS), and AC Immune (ACIU). These companies are all part of the "pharmaceutical preparations" industry.
Nuvectis Pharma (NASDAQ:NVCT) and Corbus Pharmaceuticals (NASDAQ:CRBP) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their dividends, institutional ownership, valuation, media sentiment, community ranking, analyst recommendations, risk, profitability and earnings.
Nuvectis Pharma has higher earnings, but lower revenue than Corbus Pharmaceuticals. Corbus Pharmaceuticals is trading at a lower price-to-earnings ratio than Nuvectis Pharma, indicating that it is currently the more affordable of the two stocks.
In the previous week, Corbus Pharmaceuticals had 6 more articles in the media than Nuvectis Pharma. MarketBeat recorded 7 mentions for Corbus Pharmaceuticals and 1 mentions for Nuvectis Pharma. Corbus Pharmaceuticals' average media sentiment score of 0.02 beat Nuvectis Pharma's score of 0.00 indicating that Corbus Pharmaceuticals is being referred to more favorably in the news media.
96.8% of Nuvectis Pharma shares are owned by institutional investors. Comparatively, 64.6% of Corbus Pharmaceuticals shares are owned by institutional investors. 38.9% of Nuvectis Pharma shares are owned by insiders. Comparatively, 4.0% of Corbus Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.
Nuvectis Pharma presently has a consensus price target of $21.00, indicating a potential upside of 216.74%. Corbus Pharmaceuticals has a consensus price target of $69.33, indicating a potential upside of 37.81%. Given Nuvectis Pharma's higher probable upside, equities analysts plainly believe Nuvectis Pharma is more favorable than Corbus Pharmaceuticals.
Corbus Pharmaceuticals received 425 more outperform votes than Nuvectis Pharma when rated by MarketBeat users. However, 88.89% of users gave Nuvectis Pharma an outperform vote while only 66.41% of users gave Corbus Pharmaceuticals an outperform vote.
Corbus Pharmaceuticals' return on equity of -135.17% beat Nuvectis Pharma's return on equity.
Nuvectis Pharma has a beta of 0.49, meaning that its stock price is 51% less volatile than the S&P 500. Comparatively, Corbus Pharmaceuticals has a beta of 2.52, meaning that its stock price is 152% more volatile than the S&P 500.
Summary
Corbus Pharmaceuticals beats Nuvectis Pharma on 8 of the 15 factors compared between the two stocks.
Get Nuvectis Pharma News Delivered to You Automatically
Sign up to receive the latest news and ratings for NVCT and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding NVCT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Nuvectis Pharma Competitors List
Related Companies and Tools
